1997
Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study
MCDOUGLE C, HOLMES J, BRONSON M, ANDERSON G, VOLKMAR F, PRICE L, COHEN D. Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 1997, 36: 685-693. PMID: 9136504, DOI: 10.1097/00004583-199705000-00020.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderDevelopmental disordersRisperidone treatmentClinical Global Impression ScaleOpen-label studyOpen-label trialPlacebo-controlled studyCommon side effectsEfficacy of risperidoneShort-term safetyGlobal Impression ScaleGlobal improvement itemBehavioral ratingsChildhood disintegrative disorderSocial relatednessTreatment of childrenAsperger's disorderRepetitive behaviorsAutistic disorderBehavioral symptomsBaseline visitMean ageImpression ScaleAdolescentsOptimal dose
1996
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L. A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder. JAMA Psychiatry 1996, 53: 1001-1008. PMID: 8911223, DOI: 10.1001/archpsyc.1996.01830110037005.Peer-Reviewed Original ResearchConceptsStudy of FluvoxamineAutistic disorderSelective serotonin uptake inhibitorAdverse cardiovascular eventsPlacebo-controlled trialWeeks of treatmentSerotonin uptake inhibitorSerotonin neurotransmitter systemShort-term treatmentCardiovascular eventsPlacebo groupMild sedationNeurotransmitter systemsTreatment responseSafe drugUptake inhibitorFluvoxamineSymptoms of autismFluvoxamine maleateDisordersPlaceboAutistic behaviorPatientsAdultsSymptoms